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Introduction
Primary aldosteronism (PA) — the excessive secretion of  aldosterone independent of  angiotensin II — 
is regarded as the most prevalent form of  endocrine hypertension. Patients with PA can be subdivided 
into those affected by bilateral hyperplasia and those with the unilateral form of  the disease that usually 
relates to the presence of  an aldosterone-producing adenoma (APA) of  the adrenal cortex. Clinically, PA 
is characterized by high blood pressure, electrolyte disturbances, and the development of  excessive cardio-
vascular complications compared with essential hypertension (1, 2). The diagnosis of  APA is of  particular 
importance because this condition can be cured by unilateral adrenalectomy. However, the likelihood of  
complete clinical success after surgery varies widely between clinical centers and individual patients (3).
IHC with newly available specific monoclonal antibodies has been proved very useful in providing a 
histopathological diagnosis of  PA by quantification and localization of  steroidogenic enzymes, such as aldo-
sterone synthase (cytochrome P450, family 11, subfamily B, polypeptide 2: CYP11B2) (4, 5). Further in-depth 
molecular characterization has become possible more recently by means of  high-throughput “omics” technol-
ogies, including exome sequencing, transcriptomics (6), and methylomics (7, 8). In particular, exome sequenc-
ing has contributed to uncovering genes (including KCNJ5, ATP1A1, ATP2B3, CACNA1D, CACNA1H, and 
CTNNB1) in which specific gain-of-function mutations result in autonomous aldosterone production (9–13). 
Recent genetic examinations and multisteroid profiles have provided the basis for subclassification 
of aldosterone-producing adenomas (APAs). The objective of the current study was to produce 
a comprehensive, high-resolution mass spectrometry imaging (MSI) map of APAs in relation 
to morphometry, immunohistochemical profiles, mutational status, and clinical outcome. The 
study cohort comprised 136 patients with unilateral primary aldosteronism. Matrix-assisted 
laser desorption/ionization–Fourier transform–ion cyclotron resonance MSI was conducted, and 
metabolite profiles were analyzed with genotype/phenotype information, including digital image 
analysis from morphometry and IHC of steroidogenic enzymes. Distinct molecular signatures 
between KCNJ5- and CACNA1D-mutated APAs with significant differences of 137 metabolites, 
including metabolites of purine metabolism and steroidogenesis, were observed. Intratumor 
concentration of 18-oxocortisol and 18-hydroxycortisol were inversely correlated with the staining 
intensity of CYP11B1. Lower staining intensity of CYP11B1 and higher levels of 18-oxocortisol were 
associated with a higher probability of complete clinical success after surgery. The present study 
demonstrates distinct metabolomic profiles of APAs in relation to tumor genotype. In addition, 
we reveal an inverse correlation between cortisol derivatives and CYP11B1 and the impact of 
18-oxocortisol and CYP11B1 on clinical outcome, which provides unprecedented insights into the 
pathophysiology, clinical features, and steroidogenesis of APAs.
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In addition to these genomic studies, information from multisteroid analyses have specified and extended the 
endocrine spectrum of PA (14, 15). Based on 24-hour urine steroid profiles, it has been demonstrated that a 
substantial subgroup of  patients with PA are characterized by increased glucocorticoid output in addition to 
aldosterone excess (15). Furthermore, steroid profiles from adrenal venous and peripheral plasma from APA 
patients were shown to carry information on the presence of  somatic mutations of  the adenoma (14).
The ability of  mass spectrometry imaging (MSI) to localize biomolecules in tissues without prior 
knowledge of  their presence has recently led to a rapid and substantial impact on translational and clinical 
research by uncovering molecular changes associated with disease. A broad spectrum of  analytes, includ-
ing proteins, protein modifications, peptides, drugs and their related metabolites, endogenous cell metabo-
lites, lipids, contrast agents, and other molecules, have been made accessible by this in situ technique (16). 
In addition to the intensities of  mass spectrometry, MSI studies by high-resolution matrix-assisted laser 
desorption/ionization–Fourier transform–ion cyclotron resonance (MALDI-FT-ICR) permit correlations 
with the spatial information conveyed by conventional histology. This technique has recently allowed us to 
refine the functional anatomy of  the human adrenal gland, which supports the usefulness of  these analyses 
for steroid-producing tissues also (17).
Here, we report what we believe is the first comprehensive MSI study of  APAs including genotype/
phenotype information and digital image analysis from morphometry and IHC of  steroidogenic enzymes to 
gain further insights into APA pathogenesis and clinical outcome of  patients with this condition.
Results
Demographics. Clinical characteristics of  the 136 patients with APA (77 men and 59 women, age at adre-
nalectomy 50.7 ± 10.0 years) are described and stratified by clinical outcome in Table 1. Clinical outcomes 
were evaluated based on the recently established international consensus on surgery outcomes for unilater-
al PA (3). For 132 patients on which genetic annotations were available, the following APA genotypes were 
present: 53 (40.2%) without a recurrent mutation in exome or Sanger sequencing, referred to as wild-type; 
49 (37.1%) KCNJ5 mutations; 9 (6.8%) ATP1A1 mutations; 6 (4.6%) ATP2B3 mutations; 11 (8.3%) CAC-
NA1D mutations; 2 (1.5%) CTNNB1 mutations; and 2 (1.5%) PRKACA mutations.
Morphometry and genotype correlation. Following the described workflow (Supplemental Figure 1; sup-
plemental material available online with this article; https://doi.org/10.1172/jci.insight.130356DS1), first, 
H&E sections from the TMA, consisting of  samples from 136 patients with APA, were analyzed by mor-
phometry as a method of  computer-assisted pattern recognition. Among data from color and shape parame-
ters of  nucleus and cytoplasm, the standard deviation of  nuclear size and brightness of  cytoplasm was signifi-
cantly correlated with genotypes. Higher standard deviation of  nuclear size was observed in KCNJ5-mutated 
APAs in comparison with wild-type, ATP1A1-, and CACNA1D-mutated APAs (adjusted P < 0.001; Figure 1, 
A and B). Higher brightness of  cytoplasm was also observed in KCNJ5-mutated APAs in comparison with 
wild-type and ATP1A1-mutated APAs (adjusted P = 0.022; Supplemental Figure 2, A and B).
Steroidogenic enzyme expression and genotype/phenotype correlation. In addition to morphometry, IHC of ste-
roidogenic enzymes, including CYP11B1, CYP11B2, CYP17A1, HSD3B1, and HSD3B2, was performed, and 
staining intensities were assessed by digital image analysis. Correlations between immunohistochemical staining 
and steroidogenic enzyme expression are summarized in Table 2, which indicates a variety of significant cor-
relations. For example, staining intensities of CYP11B1 were positively correlated with those of CYP17A1 (rs = 
0.515, and P < 0.001) and HSD3B1 (rs = 0.355, and P < 0.001) but inversely correlated with those of CYP11B2 
(rs = –0.414, and P < 0.001) and HSD3B2 (rs = –0.343, and P < 0.001). Relationships between staining intensities 
of steroidogenic enzymes and genotypes were further examined. According to these analyses, staining intensi-
ties of CYP11B1 in KCNJ5-mutated APAs were significantly lower in comparison with wild-type (P = 0.004) 
without further relevant genotype-dependent variations (Figure 1C and Supplemental Table 1). Staining intensi-
ties for CYP11B2 were elevated in ATP1A1-mutated APAs in comparison with KCNJ5-mutated (P < 0.001) and 
CACNA1D-mutated (P = 0.021) APAs (Figure 1D).
Metabolome profiles in correlation to genotypes. Following MALDI-FT-ICR MSI analysis, unguided 
hierarchical clustering analysis of  the whole data set failed to distinguish unequivocal clusters (Supple-
mental Figure 3A). Based on these initial heterogeneous profiles, comparisons of  individual genotype 
pairs were performed. These analyses unraveled distinct metabolome profiles between KCNJ5- and 
CACNA1D-mutated APAs (Figure 2A), which were supported on the basis of  ortho-PLSDA clustering 
(Figure 2B). Among approximately 371 m/z species, which were extracted by matrix cleaning, over 
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a mass range of  50 to 1000 m/z, 137 metabolites were significantly different (adjusted P < 0.05) in 
KCNJ5- and CACNA1D-mutated APAs. Furthermore, pathway analysis based on significantly altered 
metabolites was performed and revealed activation of  purine metabolism in KCNJ5-mutated APAs 
(pathway impact = 0.13, P < 0.001, and FDR < 0.001). Specifically, higher intensities of  metabolites, 
such as AMP (m/z 328.045), ADP (m/z 408.0115), and d-Ribulose 5-phosphate (m/z 211.001), were 
Table 1. Clinical characteristics of the 136 patients with APA included in the analysis, with stratification by clinical outcome
n Total cohort Complete Partial Absent P value Complete 
vs.  
partial
Complete 
vs.  
absent
Partial 
vs. 
absent
Complete 
vs. partial 
plus 
absent
Complete 
plus 
partial vs. 
absent
Complete 
vs.  
absent
Clinical outcome 121 24 (20%) 66 (54%) 31 (26%)
Sex (M/F) 136
 Female 59 (43%) 14 (58%) 31 (47%) 10 (32%) 0.141 NA NA NA 0.176 0.098 0.062
 Male 77 (57%) 10 (42%) 35 (53%) 21 (68%)
Age at onset of 
hypertension (years)
136 39.5 (8.8) 38.1 (8.1) 39.1 (9.0) 40.5 (9.6) 0.588 NA NA NA 0.469 0.360 0.318
Age at adrenalectomy 
(years)
136 50.7 (10.0) 44.3 (7.6) 49.9 (9.5) 55.7 (9.5) <0.001 0.032 <0.001 0.012 <0.001 <0.001 <0.001
Years of hypertension 
before adrenalectomy
136 11.1 (9.7) 6.2 (8.6) 10.8 (8.5) 15.2 (12.2) 0.003 0.075 0.002 0.075 0.007 0.006 0.003
Maximal tumor size 
(mm)
136 15 (10–18) 16 (13–19) 14 (9–18) 16 (9–18) 0.101 NA NA NA 0.048 0.851 0.276
BMI 126 28.4 (4.9) 25.2 (3.6) 29.6 (5.1) 27.9 (4.4) <0.001 <0.001 0.131 0.291 <0.001 0.598 0.024
SBP (mmHg) 136 154.3  
(21.1)
146.9  
(24.6)
156.2  
(18.6)
155.5  
(22.0)
0.161 NA NA NA 0.056 0.688 0.178
DBP (mmHg) 136 101.6  
(18.6)
102.0  
(29.9)
102.9  
(15.2)
99.7  
(16.3)
0.751 NA NA NA 0.984 0.465 0.724
Potassium (mmol/l) 135 2.9  
(2.6–3.3)
2.9  
(2.6–3.1)
2.9  
(2.6–3.2)
2.8  
(2.6–3.3)
0.880 NA NA NA 0.982 0.625 0.779
Aldosterone (ng/l; 
upper cutoff: 353)
135 266  
(154–445)
276  
(170–433)
250  
(147–447)
266  
(155–466)
0.948 NA NA NA 0.897 0.808 0.98
Renin (mU/l; normal 
range: 2.8–46.1)
135 3.1  
(2.0–6.0)
3.3  
(2.0–4.6)
3.0  
(2.0–5.7)
4.0  
(2.0–9.1)
0.246 NA NA NA 0.469 0.098 0.187
ARR (ng/mU; lower 
cutoff: 12.0)
135 75  
(39–138)
90  
(58–154)
81  
(36–151)
48  
(32–105)
0.145 NA NA NA 0.185 0.077 0.042
Lateralization index 122 12.5  
(6.3–35.2)
10.5  
(6.3–19.5)
16.7  
(6.5–47.6)
11.2  
(6.6–21.1)
0.239 NA NA NA 0.228 0.424 0.65
Contralateral ratio 120 0.3  
(0.2–0.8)
0.2  
(0.1–0.4)
0.4  
(0.2–1.0)
0.3  
(0.3–0.8)
0.068 NA NA NA 0.023 0.279 0.037
Cortisol (μg/dl; 
normal range: 
1.8–24.0)
103 12.6  
(9.1–17.8)
12.1  
(9.9–15.6)
12.6  
(9.6–16.6)
14.2  
(9.0–21.3)
0.769 NA NA NA 0.521 0.621 0.489
Cortisol after 1 mg 
DST (μg/dl; upper 
cutoff: 1.8)
38 1.4  
(1.1–1.8)
1.0  
(0.8–1.6)
1.4  
(1.2–1.8)
1.5  
(1.2–1.8)
0.565 NA NA NA 0.300 0.824 0.458
Late-night salivary 
cortisol (ng/ml; upper 
cutoff: 1.8)
61 1.0  
(0.6–2.1)
0.7  
(0.6–1.0)
1.4  
(0.7–2.2)
1.0  
(0.6–1.6)
0.344 NA NA NA 0.432 0.342 0.746
24-hour urinary free 
cortisol (μg/24h)
43 212  
(178–304)
240  
(160–289)
230  
(181–330)
189  
(140–261)
0.453 NA NA NA 0.185 0.228 0.726
KCNJ5 mutation 132
 Positive 49 (37%) 14 (61%) 23 (37%) 7 (23%) 0.018 0.016 0.053 0.006
 Negative 83 (63%) 9 (39%) 40 (63%) 24 (77%)
Data are mean (SD), n (%), n/N (%), or median (IQR). All variables refer to preoperative data unless stated otherwise. P values of less than 0.05 were 
considered significant and are shown in bold. Adrenal nodule refers to diameter of largest nodule at pathology. Lateralisation index: ([aldosterone]/[cortisol]
dominant adrenal vein)/([aldosterone]/[cortisol]nondominant adrenal vein). Contralateral ratio: ([aldosterone]/[cortisol]nondominant adrenal vein)/([aldosterone]/[cortisol]peripheral vein). NA, 
not applicable; SBP, systolic blood pressure; DBP, diastolic blood pressure; ARR, aldosterone/renin ratio; DST, dexamethasone suppression test.
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observed in KCNJ5-mutated APAs (Figure 2C). Considering all genotypes, we could demonstrate a 
positive correlation between tumor size and AMP (rs = 0.198, and P = 0.021) and ADP (rs = 0.239, and 
P = 0.005), respectively. A significantly lower abundance of  1-phosphatidyl-d-myo-inositol, which is 
an intermediate in inositol phosphate metabolism, was observed in KCNJ5-mutated APAs (adjusted 
P = 0.009, Figure 2D). Among all measured m/z species, 18-hydroxycortisol (m/z 377.2) and 18-oxo-
cortisol (m/z 375.185) were successfully annotated metabolites involved in the steroidogenic pathway. 
Both of  these 18-hybrid steroids were found with a higher abundance in KCNJ5-mutated APAs (Figure 
2E). Additional clustering analyses focused on other specific parameters, such as the specific KCNJ5 
mutation status (G151R vs. L168R, Supplemental Figure 3B) and serum cortisol values following 1 mg 
DST (high of  >1.8 μg/dl vs. low of  ≤1.8 μg/dl) (Supplemental Figure 3C), were performed, which did 
not reveal any distinct metabolomic pattern.
Figure 1. Comparison of morphometric features and genotypes of 132 APA samples. Representative images of H&E staining and morphometric anal-
ysis (A) (scale bar: 50 μm), with standard deviation of nuclear size with respect to genotypes, indicating nuclear variability in KCNJ5-mutated samples 
(adjusted P < 0.001) (B). Quantification of staining intensities for steroidogenic enzymes correlated with mutation status, demonstrating lower CYP11B1 
expression in KCNJ5-mutated tumors (C) and higher CYP11B2 expression in ATP1A1-mutated tumors (D). Median intensity of 3 cores from each patient 
was used for IHC profiles of steroidogenic enzymes. Kruskal-Wallis test was used for statistical analysis. *P < 0.05; **P < 0.01. The box plots depict the 
minimum and maximum values (whiskers), the upper and lower quartiles, and the median. The length of the box represents the interquartile range.
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Correlation of  tumor steroid metabolite content and steroidogenic enzyme expression. To explore the correla-
tion between cellular steroid concentration and steroidogenic enzyme distribution in APAs, comparisons 
between 18-oxocortisol and 18-hydroxycortisol intensities and IHC staining pattern were carried out for 
all genotypes. Both 18-oxocortisol and 18-hydroxycortisol content were inversely correlated with staining 
intensities for CYP11B1 (rs = –0.345, and P < 0.001; rs = –0.302, and P < 0.001, respectively; Supplemental 
Table 2) and CYP17A1 (rs = –0.171, and P = 0.002; rs = –0.165, and P = 0.002, respectively). In contrast, 
those of  CYP11B2 were positively correlated only with the intensities of  18-hydroxycortisol (rs = 0.107, and 
P = 0.039). Following this initial analysis, correlations were restricted to KCNJ5-mutated APAs, in which 
18-hybrid steroids were found to be more abundantly distributed. Similar to the whole data set, intensities 
of  both 18-oxocortisol and 18-hydroxycortisol were strongly inversely correlated with staining intensities of  
CYP11B1 (rs = –0.421, and P < 0.001; rs = –0.367, and P < 0.001, respectively) and CYP17A1 (rs = –0.293, 
and P < 0.001; rs = –0.345, and P < 0.001, respectively; Figure 3A and Supplemental Table 2). In addition, 
a further inverse correlation between 18-hydroxycortisol and HSD3B2 staining was found (rs = –0.247, and 
P = 0.009). Multiple regression analysis showed a relationship between staining intensities of  CYP11B1 
and intensities of  both 18-oxocortisol (P < 0.001, Supplemental Table 3) and 18-hydroxycortisol (P = 
0.041, Supplemental Table 3), suggesting that cores with lower expression of  CYP11B1 were associated 
with higher intensities of  both 18-hybrid steroids (example provided in Figure 3B). In addition, a relation-
ship between staining intensities of  CYP17A1 and 18-oxocortisol was evident (P = 0.031, Supplemental 
Table 3). Following this initial analysis, we further subdivided APAs in those with low and high CYP17A1 
expression. In both groups the inverse correlation between CYP11B1 and 18-oxocortisol remained highly 
significant (rs = –0.277, and P < 0.001; and rs = –0.306, and P < 0.001, respectively; Supplemental Table 4). 
In addition, a positive correlation between CYP17A1 and 18-oxocortisol (rs = 0.213, and P = 0.005, Supple-
mental Table 4) was evident in tissues with an overall lower-than-median intensity of  CYP17A1 (examples 
provided in Figure 3C), while an inverse correlation between these parameters was found in tissues with a 
higher-than-median intensity of  CYP17A1 (rs = –0.226, and P = 0.003; Supplemental Table 4 and example 
provided in Supplemental Figure 4).
Impact of  IHC and metabolic profiles on clinical outcome. Metabolomic parameters and IHC-based profiles 
were further correlated with clinical annotations at baseline and during follow-up after surgical therapy. 
According to these studies, intensities of  18-oxocortisol were positively correlated with tumor size (rs = 0.218, 
and P = 0.011) and inversely correlated with DBP (rs = –0.232, and P = 0.007) and 24-hour urinary free cor-
tisol (rs = –0.365, and P = 0.016). In addition, intensities of  18-hydroxycortisol were inversely correlated with 
DBP (rs = –0.173, and P = 0.044). Notably, a strong correlation between plasma 18-oxocortisol and tissue 
18-oxocortisol (rs = 0.321, and P = 0.009) and a weak correlation between plasma and tissue 18-hydroxycorti-
sol (rs = 0.209, and P = 0.095) were evident. With regard to clinical outcome, patients with complete clinical 
success showed lower staining intensities of  CYP11B1 in comparison with those with partial clinical success 
(P = 0.006) and absent clinical success (P < 0.001, Figure 4A and Supplemental Table 5). Conversely, there 
was no significant correlation between staining intensities of  CYP11B2 and clinical outcome (P = 0.449, 
Figure 4B). In addition, APAs from patients with absent clinical success showed lower staining intensities of  
HSD3B2 in comparison with those with partial clinical success (P = 0.043, Supplemental Table 5). Further-
more, patients with complete clinical success had higher tumor intensities of  18-oxocortisol in comparison 
with those with partial clinical success (P = 0.036, Figure 4C) and those with partial plus absent clinical suc-
cess (P = 0.015, Figure 4D). To clarify whether IHC and metabolic profiles are independently associated with 
Table 2. Correlations between staining intensities of steroidogenic enzymes
CYP11B2 CYP17A1 HSD3B1 HSD3B2
rs P value rs P value rs P value rs P value
CYP11B1 –0.414 <0.001 0.515 <0.001 0.355 <0.001 –0.343 <0.001
CYP11B2 – – –0.486 <0.001 –0.110 0.037 0.602 <0.001
CYP17A1 – – 0.170 0.002 –0.260 <0.001
HSD3B1 – – –0.178 0.002
P values of less than 0.05 were considered significant and are shown in bold.
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Figure 2. Metabolome features of 60 APA samples. Unguided hierarchical clustering analysis (A) and orthogonal partial least squares discrimi-
nant analysis (ortho-PLSDA) (B) of metabolome profiles between APAs with KCNJ5 and CACNA1D mutations. (C) Shown are significant differences 
in metabolites of the purine metabolism and intensities of adenosine monophosphate (AMP), adenosine diphosphate (ADP), and d-Ribulose 
5-phosphate between KCNJ5- and CACNA1D-mutated APAs (adjusted P = 0.010, 0.003, and 0.047, respectively). (D) Intensities of 1-phosphati-
dyl-d-myo-inositol between KCNJ5- and CACNA1D-mutated APAs (adjusted P = 0.009). *adjusted P < 0.05; **adjusted P < 0.01. (E) Significant 
changes in intensities between KCNJ5- and CACNA1D-mutated APAs of 18-oxocoritsol (P = 0.020) and 18-hydroxycortisol (P < 0.001). Mann-Whitney 
U test was used for statistical analysis. *P < 0.05; **P < 0.01. The box plots depict the minimum and maximum values (whiskers), the upper and 
lower quartiles, and the median. The length of the box represents the interquartile range.
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Figure 3. Correlations between IHC of steroidogenic enzymes and metabolic profiles of 18-hydroxycortisol and 18-oxocortisol. (A) Heatmap visual-
izations of relationships between IHC and 18-oxocortisol and 18-hydroxycortisol in 49 KCNJ5-mutated APAs with results of Spearman’s rank correlation 
coefficient. (B) Representative images of 18-oxocortisol (red) and 18-hydroxycortisol (green) expression from cores with high and low staining intensity 
of CYP11B1. (C) Comparison of immunohistochemistry of CYP11B1 and CYP17A1 and 18-oxocortisol expression (red) in cores with lower-than-median 
expression of CYP17A1. Scale bars: 500 (metabolites), 50 μm (IHC).
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clinical outcome, logistic regression analyses were performed. We thereby identified factors independently 
associated with complete clinical success by comparing the proportion of  patients with complete clinical 
success with those with partial and absent clinical success combined. Following this approach, complete clin-
ical success was associated with lower age, lower BMI, and lower staining intensities of  CYP11B1 or higher 
intensities of  18-oxocortisol (Table 3), while stepwise regression analysis rejected clinical parameters such as 
maximal tumor size, lateralization index, and KCNJ5 mutation status. Younger age and lower staining intensi-
ties of  CYP11B1 or higher staining intensities of  HSD3B2 were independently associated with clinical benefit 
when the proportion of  patients with complete and partial clinical success combined was compared with the 
proportion of  those with absent clinical success (Table 3). In a comparison of  complete with absent success, 
younger age and lower staining intensities of  CYP11B1 were associated with clinical success (Table 3), while 
stepwise regression rejected clinical parameters such as BMI, contralateral ratio, and KCNJ5 mutation status. 
Logistic regression analyses were also performed to identify further metabolomic factors independently asso-
ciated with clinical success. As shown in Supplemental Tables 6, metabolites were associated with complete 
clinical success in comparison with those with partial and absent clinical success combined.
Figure 4. IHC and metabolic profiles on clinical outcome of 136 patients with APA. Staining intensities of steroidogenic enzymes with regard to clinical 
outcome: CYP11B1 (P < 0.001) (A) and CYP11B2 (P = 0.449) (B). Intensities of 18-oxocortisol in relation to clinical outcome: comparison among complete, 
partial, and absent success in clinical outcome (P = 0.041) (C) and that between complete and partial plus absent success in clinical outcome (P = 0.015) 
(D). Intensities of 3 cores from each patient were classified into highest, median, and lowest intensity. Median intensity of 3 cores from each patient was 
used for analysis. Mann-Whitney U test and Kruskal-Wallis test were used for statistical analysis. *P < 0.05; **P < 0.01. The box plots depict the minimum 
and maximum values (whiskers), the upper and lower quartiles, and the median. The length of the box represents the interquartile range.
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Discussion
Herein, we report an integrated approach of  MALDI metabolite imaging, morphometry, and quantifi-
cation of  steroid enzyme expression in APAs to allow deep insights into pathophysiological and clini-
cal features of  APAs and associated steroidogenesis. Based on these analyses, we can provide findings in 
pathways and intratumor steroid enzymes in a genotype-dependent manner that had not been appreciated 
before and that correlate with clinical outcome.
One of  the important findings of  our report relates to morphometry, which provides a rich source 
of  information that can be assessed in a quantitative manner. Classification of  zona glomerulosa–like 
(ZG-like) adenomas with small, compact cells, with high nuclear/cytoplasmic ratio and moderate 
amount of  lipid, and zona fasciculata–like (ZF-like) adenomas with large, lipid-laden clear cells, with 
round to oval vesicular nuclei, has been described (18, 19). KCNJ5-mutated APAs were suggested to be 
composed mainly of  ZF-like cells, while ATP1A1- and CACNA1D-mutated APAs more frequently pre-
sented a ZG-like phenotype (20, 21). However, quantitative assessment of  these observations had been 
difficult. Our morphometry analysis, which is a method of  computer-assisted pattern recognition, 
enabled us to quantify color and shape parameters independent of  observer bias. Among parameters 
with significant differences between genotypes in our analysis, higher brightness of  the cytoplasm in 
KCNJ5-mutated APAs likely reflects the lipid-rich cytoplasm of  ZF-like cells. Standard deviation of  
nuclear size was also found as a parameter in correlation with genotypes. A previous study indicated 
that KCNJ5-mutated APAs include atypical cells with large nuclei, which were absent in ATP1A1- and 
CACNA1D-mutant APAs (21). It is possible that the finding from the current unsupervised digital 
image analysis is consistent with this observation. Although pathophysiological significance has to 
be elucidated, it is conceivable that changes in nuclear variability could reflect difference of  cellular 
origins or differentiation between those genotypes.
Digital image analysis further provided important information on the quantification of  steroidogen-
ic enzyme expression. Specifically, staining intensities of  CYP11B2 were higher in ATP1A1-mutated 
APAs, in comparison with those with KCNJ5 mutations, which is consistent with findings from a 
previous study (20). Notably, we could further demonstrate significant mutual correlations between 
steroidogenic enzyme expressions. Inverse correlations between staining intensities of  CYP11B2 and 
those of  CYP11B1 and CYP17A1 in APAs might reflect the contrasted features of  ZG-like cells, 
which include CYP11B2+ cells, and ZF-like cells, which include CYP11B1+ and CYP17A1+ cells. 
Table 3. Multivariate logistic regression analyses including IHC and metabolic profiles
Complete vs. partial plus absent
Odds ratio (95% CI) P value
Age at adrenalectomy (per year) 0.94 (0.89–1.00) 0.035
BMI (per 1 kg/m2) 0.83 (0.72–0.95) 0.009
CYP11B1 (per 0.01 unit of staining intensity) 0.79 (0.68–0.93) 0.004
Odds ratio (95% CI) P value
Age at adrenalectomy (per year) 0.93 (0.88–0.98) 0.008
BMI (per 1 kg/m2) 0.83 (0.72–0.95) 0.008
18-oxocortisol (per 0.01 unit of peak intensity) 1.10 (1.01–1.21) 0.030
Complete plus partial vs. absent
Odds ratio (95% CI) P value
Age at adrenalectomy (per year) 0.91 (0.87–0.96) <0.001
CYP11B1 (per 0.01 unit of staining intensity) 0.85 (0.76–0.96) 0.007
Odds ratio (95% CI) P value
Age at adrenalectomy (per year) 0.93 (0.88–0.98) 0.007
HSD3B2 (per 0.01 unit of staining intensity) 1.04 (1.00–1.09) 0.048
Complete vs. absent
Odds ratio (95% CI) P value
Age at adrenalectomy (per year) 0.84 (0.75–0.94) 0.002
CYP11B1 (per 0.01 unit of staining intensity) 0.68 (0.50–0.92) 0.012
P values less than 0.05 were considered significant and are shown in bold.
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Furthermore, our result showed a positive correlation between staining intensities of  HSD3B2 and 
CYP11B2 in APAs, which is consistent with the features of  ZG, in which coexpression of  HSD3B2 
and CYP11B2 has been reported (22).
Previous studies have aimed to classify APAs with regard to genotypes using various approaches, 
including clinical (23), histopathological (20, 21), steroidogenic (14), and molecular parameters (8, 24). 
The MALDI-MSI data, provided herein, add findings directed toward metabolites distributed in tumor 
tissues. Compared with the high proportion of  KCNJ5 mutation (24%–41% in Western countries) (24–28), 
the incidence of  other mutations, such as ATP1A1 (5.3%) and CACNA1D (9.3%), is rather low (23). This 
fact is likely to have contributed to a less distinct genotype/phenotype correlation. In addition, heteroge-
neous profiles of  tumors without recurrent mutations, which were observed in the initial unguided hierar-
chical clustering analysis, might have impeded the unraveling of  distinct metabolomic patterns within the 
whole cohort. However, our cohort included 11 CACNA1D-mutated APAs, which is the highest number 
reported to date used for molecular analysis of  APAs and allowed discrimination of  metabolome patterns 
between KCNJ5- and CACNA1D-mutated APAs. Among differentially present metabolites, higher intensi-
ties of  18-oxocortisol and 18-hydroxycortisol in KCNJ5-mutated APAs were concordant with findings from 
a previous study on plasma steroid concentrations (14).
Moreover, pathway analysis revealed significant changes in purine metabolism and promotion in 
purine synthesis in KCNJ5-mutated APAs. Purine nucleotides are crucial for providing cellular energy and 
affect intracellular signaling (29). Based on clinical observations, it is well appreciated that APAs with 
KCNJ5 mutation are characterized by a larger tumor size (23), which is recapitulated in the current data 
set with significantly larger KCNJ5 tumors in comparison with those with CACNA1D mutations (data not 
shown). Considering that an increase in purine synthesis might reflect the promotion of  cell cycle and pro-
liferation, the observed larger tumor size and promotion of  purine synthesis in APAs with KCNJ5 mutation 
could be connected by means of  active cell proliferation. In fact, considering all genotypes, we were able 
to demonstrate a positive correlation between tumor size and tumor AMP and ADP content, respectively. 
Furthermore, purines, including ATP, ADP, and AMP, have been shown to stimulate steroidogenesis in 
bovine adrenal cells (30) potentially by inhibition of  noninactivating K+ current, thereby modulating the 
resting membrane potential (31) and increasing intracellular Ca2+ levels (32). Therefore, it is prudent to 
speculate that abundant purines in KCNJ5-mutated APAs could contribute to or modify steroidogenesis 
as auto- or paracrine signals. Together, the evidence from the literature and our current findings highlight 
the importance of  purine metabolism in adrenal (patho-) physiology. We appreciate that the direct link and 
causal relationship between KCNJ5-activating mutations and purine-dependent signaling in APAs remain 
uncertain and will require more directed mechanistic studies.
It is also noteworthy that lower amounts of  1-phosphatidyl-d-myo-inositol, which is generated from 
1-phosphatidyl-d-myo-inositol-5-phosphate via the enzyme 1-phosphatidyl-d-myo-inositol-5-phosphate 
4-kinase (PIP4K II), is evident in KCNJ5-mutated APAs. Because negative effects of  PIP4Ks on PI3K/Akt 
signaling have been suggested in previous studies (33, 34), lower activity of  PIP4K II indicates enhanced Akt 
activity in KCNJ5-mutated APAs. This finding is in accordance with a previous study, which reported that the 
PI3K/Akt signaling is activated in some APAs while no genotype/phenotype correlation was provided (35).
As derivatives of cortisol, 18-hydroxycortisol and 18-oxocortisol, summarized as 18-hybrid steroids, have 
been implicated in the steroidogenic profile of patients with PA. Previous studies have shown that CYP11B2 
can convert 11-deoxycortisol efficiently to 18-hydroxycortisol and 18-oxocortisol, while CYP11B1 can synthe-
size only 18-hydroxycortisol (reviewed in ref. 36). High plasma levels of 18-oxocortisol and 18-hydroxycorti-
sol have been identified in patients with KCNJ5-mutated APAs and have been shown to be predictive for the 
presence of this mutation (14). Our results provide data on increased intratumor content of 18-oxocortisol 
and 18-hydroxycortisol in KCNJ5-mutated APAs. Regarding the relationships between steroidogenic enzymes 
and steroid metabolites, significant inverse correlations between staining intensities of CYP11B1 and stain-
ing intensities of 18-hybrid steroids were evident independent of the somatic genotype. Low expression of  
CYP11B1 may expose CYP11B2 to higher levels of 11-deoxycortisol and allow for efficient conversion toward 
18-hybrid steroids. Furthermore, our analyses suggest a contribution of CYP17A1 to the production of 18-oxo-
cortisol. Considering that CYP17A1 generates upstream substrates of 11-deoxycortisol, relationships between 
higher staining intensities of CYP17A1 and abundance of 18-oxocortisol were expected. Surprisingly, our 
analysis revealed that positive correlations between CYP17A1 and 18-oxocortisol are present only in tissues 
with a lower-than-median staining intensity of CYP17A1. These findings might thereby indicate a threshold, 
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below which the amount of CYP17A1 can affect the production of 18-oxocortisol. On the other hand, our 
findings indicate that CYP11B2 expression levels in APAs are not significantly correlated with the production 
of 18-oxocortisol and 18-hydroxycortisol. One explanation of this finding is that all APA tissues are character-
ized by high CYP11B2 expression levels above a threshold, which would be critical to detect any difference in 
18 steroid levels. Current MALDI-MSI techniques are restricted to a subset of steroids that can be identified 
and quantified. Future adaptations of analytical protocols would be necessary to overcome these limitations 
and to provide further insights into steroidogenesis in a spatial manner.
The power of  digital image analysis provided us findings about relationships between clinical out-
come and tumor metabolite content and steroidogenic enzyme expression in APA tissues. It is there-
fore the first report to our knowledge that provides a correlation of  18-oxocortisol tumor content and 
CYP11B1 expression levels with outcome independent of  clinical parameters, such as age at adrenalec-
tomy (37). Significant inverse correlation between the intensities of  18-oxocortisol and CYP11B1 may 
explain in part the correlation between metabolite profiles and clinical parameters. For example, an 
inverse correlation of  24-hour urinary free cortisol and the intensity of  18-oxocortisol might be due to 
the abundance of  CYP11B1, which promotes cortisol production in APA tissues. Two previous studies 
revealed that glucocorticoid cosecretion in APAs is frequently found, and several surrogate parame-
ters of  metabolic risk were correlated with glucocorticoid secretion, which suggested the concept of  
“Connshing” syndrome (15, 38). Our findings showed the importance of  distribution of  CYP11B1 in 
tumor tissues, not that of  CYP11B2, with respect to clinical outcome and provided new insights into this 
concept. Overall, our findings suggest that information on tumor metabolites and steroidogenic enzyme 
expression could aid the prediction of  long-term clinical outcome and therefore might help define the 
intensity of  clinical follow-up and indication of  accompanying medical intervention.
The present study indicates distinct metabolomic profiles of  APAs with regard to mutation status 
between KCNJ5 and CACNA1D. In addition, we reveal an inverse correlation between 18-oxocortisol and 
18-hydroxycortisol and CYP11B1 expression. The impact of  18-oxocortisol and CYP11B1 on clinical out-
come is demonstrated, which provides potentially unprecedented insights into the pathophysiology, clinical 
features, and steroidogenesis of  APAs.
Methods
Patient cohort
The study cohort comprised 136 patients with unilateral PA, who had been diagnosed and surgically treat-
ed at a referral center (Klinikum der Universität München, Munich, Germany). The diagnosis of  PA was 
established according to current Endocrine Society Guidelines (39). Baseline and follow-up clinical infor-
mation was collected prospectively as part of  the German Conn registry. Specific details for PA diagnosis 
and adrenal venous sampling procedures have been described elsewhere (40).
DNA sequencing
Detection of  somatic mutations in APAs. In 45 cases, exome sequencing of  frozen tumor samples was 
performed as described previously (10). From 87 samples, targeted sequencing of  APA-related genes 
(KCNJ5, ATP1A1, ATP2B3, CACNA1D, CTNNB1, and PRKACA) was performed following polymerase 
chain reaction and direct sequencing. Detailed methods, including primer information, have been 
described previously (10, 23, 41).
Tissue microarrays, IHC, and digital image analysis. Tissue microarrays were constructed by sampling of 3 
tumor tissue cores (1.0 mm in diameter) as previously described (42). Paraffin-embedded tissue blocks were used 
upon selection on the basis of representative H&E-stained tissue sections of each case by the same pathologist.
The technical construction of  the tissue microarrays was performed on a manual tissue array device 
(AlphaMetrix Biotech). A semiautomated rotation microtome (Microm HM 355S, Thermo Fisher Sci-
entific) was used to cut 3-μm tissue microarray sections that were transferred to glass slides for IHC and 
H&E staining. IHC staining was performed under standardized conditions on a Discovery XT automat-
ed stainer (Ventana Medical Systems, Roche Diagnostics) using monoclonal antibodies directed against 
human (h) CYP11B1, CYP11B2, CYP17A1 (43), and HSD3B1 (22), developed by one of  the co-authors 
(CGS). Slides were incubated with primary antibodies (rat monoclonal anti-hCYP11B1 [1:20], mouse 
monoclonal anti-hCYP11B2 [1:100], mouse monoclonal anti-17α-hydroxylase [1:500], mouse monoclonal 
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anti-hHSD3B1 [1:500], or rabbit polyclonal anti-hHSD3B2 [1:250] (Abcam, Ab154385), in Dako REAL 
antibody dilution, Agilent) and detected by the Discovery DAB Map Kit (Ventana Medical Systems, Roche 
Diagnostics), including incubation with respective secondary antibodies (against CYP11B2, HSD3B1, and 
HSD3B2: antimouse and antirabbit, ready-to-use universal secondary antibody, 760-4205, Ventana Med-
ical Systems, Roche Diagnostics; against CYP11B1: antirat, ready-to-use universal secondary antibody, 
BA-4000, Vector Laboratories).
Following H&E staining and IHC, tissue microarray slides were scanned at ×20 original objective mag-
nification using a digital Mirax Desk slide scanner (Carl Zeiss Microscopy GmbH) before importing into 
the image analysis software Definiens Developer XD2 (Definiens AG), as described previously (44). Tumor 
areas were manually annotated, and a rule set was defined to detect and quantify morphometry data, includ-
ing color and shape parameters of  nucleus and cytoplasm from H&E staining, and staining intensities from 
IHC in the annotated tumor area, with operators blinded with regard to corresponding clinical annotations.
Tissue sectioning and matrix application. TMA samples were sectioned with a thickness of  4 μm and water 
bath–mounted onto indium tin oxide–coated glass slides (Bruker Daltonik GmbH). FFPE sections were 
incubated for 1 hour at 70°C, deparaffinized in xylene (2 × 8 min), and air-dried. For MALDI-MSI of  
endogenous metabolites, the matrix solution was 10 mg/ml 9-aminoacridine hydrochloride monohydrate 
matrix (9-AA) (MilliporeSigma Chemie GmbH) in water/methanol 30:70 (v/v). 9-AA was chosen as a 
matrix because it is known to exhibit very few matrix-derived interferences in the low-mass range and to 
achieve high sensitivity and high linearity in negative ion mode for a wide range of  low-molecular-weight 
metabolites (45–49). The matrix solution was sprayed on the tissue sections using a SunCollect automatic 
sprayer (SunChrom) at room temperature. The matrix application was performed at flow rates of  10, 20, 
30, and 40 μl/min, respectively, for the first 4 layers. The other 4 layers were performed at 40 μl/min.
MALDI-MSI measurement and metabolite annotation. Following tissue sample preparation, the MAL-
DI-MSI measurement was performed on a Bruker Solarix 7T FT-ICR-MS (Bruker Daltonics). The MAL-
DI-MSI data were acquired over a mass range of  m/z 50–1000. Mass imaging data were acquired in neg-
ative ionization mode with 70 μm spatial resolution using 50 laser shots at a frequency of  500 Hz. After 
the MALDI-MSI measurement, the acquired data from the tissue samples underwent spectra processing 
in FlexImaging v. 4.2 (Bruker Daltonics). Following the MALDI imaging, matrix was removed with 70% 
ethanol. Tissue sections were stained with H&E and scanned with a digital Mirax Desk slide scanner (Carl 
Zeiss Microscopy GmbH).
Metabolite annotation was performed by matching accurate mass with databases as previously 
described (49–51) (mass accuracy ≤ 4 ppm, METLIN, http://metlin.scripps.edu/; the Human Metabo-
lome Database, http://www.hmdb.ca; ref. 52). Pathway analysis was applied to identify discriminative 
features of  mutation status of  APAs. The Kyoto Encyclopedia of  Genes and Genomes database (http://
www.genome.jp/kegg/) and MetaboAnalyst 3.0 (http://www.metaboanalyst.ca) were used.
Statistics
Metabolomic analysis. MATLAB R2014b (v.7.10.0, MathWorks Inc.) was used as the MALDI spectral prepro-
cessing tool for the subsequent bioinformatics data analysis. Peak picking was performed as described in detail 
previously (50). Briefly, the parameters of  peak picking included m/z 0.0005 minimal peak width, signal-to-
noise threshold of  2, and intensity threshold of  0.01%. Isotopes were automatically identified and excluded. 
The list of  m/z species with respective intensities for ROIs were uploaded to MetaboAnalyst 3.0 (http://www.
metaboanalyst.ca) (53) and processed with a mass tolerance of  m/z 0.0001. Metabolites present in more than 
80% of patients were extracted as matrix cleaning and used for heatmap-based clustering and ortho-PLSDA, 
which were created with MetaboAnalyst, and data were exported as Figure 2B.
Correlation within tissue-derived parameters and clinical annotations. Statistical comparisons between 
morphometry or metabolome and genotypes were performed with Mann-Whitney U test or Krus-
kal-Wallis test, and P values were adjusted with the Benjamini-Hochberg method. To calculate the 
detailed relationship between profiles of  tissue-derived parameters and clinical annotations, staining 
intensities from IHC data and peak intensities from metabolites (18-oxocortisol and 18-hydroxycor-
tisol) of  3 cores from each tumor were classified into highest, median, and lowest intensity, and the 
median intensity of  3 cores from each tumor was used for the analysis with Mann-Whitney U test, 
Kruskal-Wallis test, or Spearman’s rank correlation coefficient. Spearman’s correlation coefficients are 
denoted as rs. P < 0.05 was considered significant.
1 3insight.jci.org   https://doi.org/10.1172/jci.insight.130356
R E S E A R C H  A R T I C L E
Correlations within IHC data and between IHC data and metabolome profiles were calculated at each 
core to appreciate potential intratumor heterogeneity of  steroidogenesis. Further statistical testing for asso-
ciations of  profiles of  IHC and metabolome to the clinical outcome was conducted using logistic regression. 
Covariates from clinical parameters were chosen based on Table 1 and analyzed, including profiles of  IHC 
or metabolome data using backward stepwise selection. All calculations were performed using R 3.4.3.
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